Ultrasonic Nebulizers Market to Exceed USD 325.6 million by 2031, Expanding at a CAGR of 5.4% | Exclusive Report by Transparency Market Research
21 août 2023 05h53 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global ultrasonic nebulizers market is projected to flourish at a CAGR of 5.4% from...
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
15 août 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle...
Claire’s Place Foundation Launches First East Coast Glow Ride for Cystic Fibrosis
08 août 2023 11h50 HE
|
Claire's Place Foundation
Los Angeles, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is excited to...
Claire’s Place Foundation Announces 9th Annual Glow Ride for Cystic Fibrosis
13 juil. 2023 08h00 HE
|
Claire's Place Foundation
Los Angeles, CA, July 13, 2023 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is proud to...
First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
13 juil. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
05 juil. 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
30 juin 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and...
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
28 juin 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Strengthens Intellectual Property Estate
27 juin 2023 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)
15 juin 2023 11h31 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...